Total Payments
$21,588
2023 Payments
$97.84
Companies
8
Transactions
16
Medicare Patients
403
Medicare Billing
$74,263
Payment Breakdown by Category
Research$11,290 (52.3%)
Other$10,188 (47.2%)
Food & Beverage$97.84 (0.5%)
Education$11.92 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11,290 | 6 | 52.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,188 | 5 | 47.2% |
| Food and Beverage | $97.84 | 4 | 0.5% |
| Education | $11.92 | 1 | 0.1% |
Payments by Type
Research
$11,290
6 transactions
General
$10,298
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $10,188 | 5 | $0 (2019) |
| Celgene Corporation | $8,794 | 3 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $1,643 | 2 | $0 (2020) |
| Astellas Pharma Global Development | $852.50 | 1 | $0 (2020) |
| GENZYME CORPORATION | $48.55 | 2 | $0 (2023) |
| Karyopharm Therapeutics Inc. | $26.72 | 1 | $0 (2023) |
| Merck Sharp & Dohme LLC | $22.57 | 1 | $0 (2023) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $97.84 | 4 | GENZYME CORPORATION ($48.55) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $2,353 | 2 | Novartis Pharmaceuticals Corporation ($1,500) |
| 2019 | $1,974 | 3 | Incyte Corporation ($1,088) |
| 2018 | $6,276 | 3 | Celgene Corporation ($3,444) |
| 2017 | $10,876 | 3 | Incyte Corporation ($6,412) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/15/2023 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: Oncology | ||||||
| 07/31/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $22.57 | General |
| Category: ONCOLOGY | ||||||
| 02/03/2023 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $28.83 | General |
| Category: Oncology | ||||||
| 01/24/2023 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $26.72 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 01/27/2020 | Astellas Pharma Global Development | PADCEV (Drug) | — | In-kind items and services | $852.50 | Research |
| Study: A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF ASG-22CE GIVEN AS MONOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CANCER AND OTHER MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4 • Category: ONCOLOGY | ||||||
| 01/23/2020 | Novartis Pharmaceuticals Corporation | LGK974 (Drug) | — | In-kind items and services | $1,500.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 08/13/2019 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $231.20 | General |
| 04/15/2019 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $856.50 | General |
| 03/15/2019 | Celgene Corporation | CC-115 (Drug) | — | In-kind items and services | $886.00 | Research |
| Study: Phase 1a/1b, multicenter, open label, dosefinding study to assess the safety, tolerability, pharmacokinetics & preliminary efficacy of the dual dna-pk & tor kinase inhibitor, cc-115, administered orally to subjects w/ advanced solid tumors & hematologic (CC-115-ST-001) | ||||||
| 09/25/2018 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,689.00 | General |
| 07/24/2018 | Celgene Corporation | CC-115 (Drug) | — | In-kind items and services | $3,444.00 | Research |
| Study: CC-115-ST-001 - Phase 1a/1b, multicenter, open label, dosefinding study to assess the safety, tolerability, pharmacokinetics & preliminary efficacy of the dual dna-pk & tor kinase inhibitor, cc-115, administered oral | ||||||
| 01/23/2018 | Novartis Pharmaceuticals Corporation | WNT974 (Drug) | — | In-kind items and services | $143.25 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT | ||||||
| 10/26/2017 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,792.95 | General |
| 09/26/2017 | Incyte Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $618.57 | General |
| 02/07/2017 | Celgene Corporation | Abraxane (Drug) | — | In-kind items and services | $4,464.00 | Research |
| Study: ABI-007-NSCL-005 • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABI-007-NSCL-005 | Celgene Corporation | $4,464 | 1 |
| CC-115-ST-001 - Phase 1a/1b, multicenter, open label, dosefinding study to assess the safety, tolerability, pharmacokinetics & preliminary efficacy of the dual dna-pk & tor kinase inhibitor, cc-115, administered oral | Celgene Corporation | $3,444 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,500 | 1 |
| Phase 1a/1b, multicenter, open label, dosefinding study to assess the safety, tolerability, pharmacokinetics & preliminary efficacy of the dual dna-pk & tor kinase inhibitor, cc-115, administered orally to subjects w/ advanced solid tumors & hematologic (CC-115-ST-001) | Celgene Corporation | $886.00 | 1 |
| A PHASE 1 STUDY OF THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF ASG-22CE GIVEN AS MONOTHERAPY IN SUBJECTS WITH METASTATIC UROTHELIAL CANCER AND OTHER MALIGNANT SOLID TUMORS THAT EXPRESS NECTIN-4 | Astellas Pharma Global Development | $852.50 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $143.25 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 120 | 231 | $42,172 | $20,390 |
| 2022 | 4 | 96 | 202 | $32,143 | $19,584 |
| 2021 | 4 | 102 | 183 | $29,756 | $18,103 |
| 2020 | 3 | 85 | 189 | $31,235 | $16,186 |
Total Patients
403
Total Services
805
Medicare Billing
$74,263
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 25 | 76 | $15,706 | $8,462 | 53.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 50 | 101 | $15,262 | $7,685 | 50.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 20 | 20 | $6,705 | $2,799 | 41.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 25 | 34 | $4,499 | $1,445 | 32.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 26 | 93 | $16,122 | $10,671 | 66.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 36 | 74 | $8,994 | $5,448 | 60.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $5,616 | $2,699 | 48.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 16 | 17 | $1,411 | $766.45 | 54.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 37 | 100 | $17,355 | $11,061 | 63.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 33 | 47 | $5,640 | $3,618 | 64.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $4,992 | $2,473 | 49.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 16 | 20 | $1,769 | $950.60 | 53.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 108 | $18,731 | $10,030 | 53.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 40 | 67 | $8,136 | $4,123 | 50.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 14 | 14 | $4,368 | $2,033 | 46.6% |
About Dr. David Smith, MD
Dr. David Smith, MD is a Internal Medicine healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184700056.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Smith, MD has received a total of $21,588 in payments from pharmaceutical and medical device companies, with $97.84 received in 2023. These payments were reported across 16 transactions from 8 companies. The most common payment nature is "" ($11,290).
As a Medicare-enrolled provider, Smith has provided services to 403 Medicare beneficiaries, totaling 805 services with total Medicare billing of $74,263. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Ann Arbor, MI
- Active Since 10/31/2006
- Last Updated 05/02/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1184700056
Products in Payments
- Abraxane (Drug) $4,464
- CC-115 (Drug) $4,330
- LGK974 (Drug) $1,500
- PADCEV (Drug) $852.50
- WNT974 (Drug) $143.25
- JEVTANA (Drug) $48.55
- XPOVIO (Drug) $26.72
- KEYTRUDA (Biological) $22.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Ann Arbor
Dr. Marschall Runge, Md, MD
Internal Medicine — Payments: $2.3M
Internal Medicine $2.3M
Terry Smith, M.d, M.D
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Harry Erba, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Dinesh Khanna, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Alexander Yevzlin, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Vallerie Mclaughlin, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M